A Phase 1 Multi-Dose Dose-Escalation Study of Elesclomol Sodium, Administered Once Weekly to Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2010
At a glance
- Drugs Elesclomol (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 08 Jun 2010 12-month survival results reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Synta media release.
- 27 Feb 2009 Status changed from active, no longer recruiting to discontinued. The reasons for the decision to suspend this trial have been reported in a Synta Pharmaceuticals media release.
- 12 Feb 2009 Dosing has commenced according to a Synta Pharmaceuticals media release.